Nelson Advisors Big Questions in HealthTech Series: Is the EU AI Act a moat or a millstone?

Nelson Advisors
9 minutes ago
17 min read

Moat or Millstone: Layered AI Regulation, Transatlantic Arbitrage and the Geopolitics of Frontier Innovation

The global landscape of artificial intelligence governance has crystallised into three distinct philosophical paradigms: the Rights-Based approach championed by the European Union, the Innovation-First model pursued by the Gulf Cooperation Council (GCC) and Singapore, and the State-Directed framework enforced by China. Within this geopolitical matrix, the European Union’s Artificial Intelligence Act (AI Act), which entered into force on August 1st, 2024, serves as the world's first comprehensive horizontal legislative framework for AI. Yet, as its implementation phases activate, a critical debate has emerged: is this framework a stabilising regulatory moat that guarantees safety and transparency, or is it a compliance millstone that stifles early-stage innovation and drives top-tier technical founders out of the bloc?

This tension is most acute in highly regulated sectors such as digital health and medical technology (MedTech). Here, developers face a compounding "double lock": the sector-specific demands of the Medical Device Regulation (MDR) or In Vitro Diagnostic Regulation (IVDR) paired with the horizontal, systemic risk-mitigation layers of the AI Act. This analysis evaluates the economic, operational, and structural implications of this layered regulatory environment, contrasting Europe's precautionary posture with the aggressive deregulation of the United States and the infrastructure-led, capital-rich incentives of the Gulf.

The Convergence of Global AI Governance Paradigms

The global race for artificial intelligence dominance is no longer merely a contest of algorithmic complexity or computational raw power; it has become an ideological struggle waged through legislative design. Historically, technology ecosystems thrived in regulatory vacuums, scaling rapidly before state authorities could construct guardrails. However, the unprecedented speed and societal penetration of generative and agentic artificial intelligence have forced global powers to enact simultaneous regulatory frameworks. This regulatory convergence has bifurcated the international market along philosophical lines.

The European Union's rights-based approach starts from the precautionary principle, treating systemic safety as a prerequisite for market entry. Under this model, developers must prove their systems meet fundamental rights, non-discrimination, and safety standards before deployment. In contrast, the innovation-first approach of the United States and the Gulf states views regulation as a dynamic enabler, using soft-law guidelines, trial sandboxes, and targeted exemptions to attract capital and talent.

Meanwhile, the state-directed model of China integrates AI governance directly into national security frameworks, prioritizing algorithmic alignment and content control through state registration. For early-stage founders and venture capital allocators, these diverging legal environments create a high-stakes arena for regulatory arbitrage, where the choice of a startup's launch market directly dictates its operational runway, cost structure, and survival rate.

Inside the EU AI Act: Scope, Defined Boundaries and Prohibited Risks

At the core of the European Union's regulatory strategy is a highly structured, risk-based classification system designed to govern any technical system using autonomous logic to influence physical or virtual environments. Under Article 3 of the AI Act, an artificial intelligence system is formally defined as a machine-based system designed to operate with varying levels of autonomy that may exhibit adaptiveness after deployment. Crucially, the system must infer, from the inputs it receives, how to generate outputs such as predictions, content, recommendations, or decisions that can influence real or virtual environments.

This technical definition represents a critical battlefield for startup engineering teams. The inclusion of the term "infer" explicitly distinguishes artificial intelligence from traditional, deterministic software systems. Rule-based systems defined solely by natural persons to automatically execute logical operations fall outside the scope of the AI Act. Consequently, early-stage startups are increasingly utilizing simple decision-tree rule engines as a tactical workaround to bypass the AI Act entirely during their initial development phases, explicitly documenting these architectural boundaries as a critical governance step to avoid regulatory exposure.

For systems that do fall within the scope, the AI Act imposes a rigid, four-tier risk taxonomy with escalating compliance obligations. The most immediate operational boundaries are established by Article 5, which outlines prohibited AI practices deemed incompatible with European values. These bans became fully active on February 2, 2025, and outlaw several categories of technology:

Biometric categorisation systems that use sensitive characteristics to profile individuals.
Emotion recognition systems deployed within workplaces or educational institutions, unless justified by explicit medical or safety-related criteria.
Social scoring systems run by public authorities that classify individuals based on social behavior or personality traits in a way that leads to unfavourable treatment.
Predictive policing tools that assess the likelihood of an individual committing a criminal offense based solely on profiling or personality traits.

Failing to align with these prohibitions represents an existential threat to corporate stability. Violating Article 5 prohibitions triggers severe financial penalties, reaching up to €35 million or 7% of a company’s total worldwide annual turnover, whichever is higher. Furthermore, the operational fallout is often more damaging than the financial fine, as a regulatory order to withdraw or ban an AI tool can halt critical corporate functions overnight.

Beyond prohibited systems, the AI Act introduces stringent obligations for developers of General Purpose AI (GPAI) models. Providers of GPAI engines, such as large language models trained on massive, unstructured datasets, must maintain comprehensive technical documentation, detail their training and evaluation processes, publish summaries of their training data, and actively respect the EU Copyright Directive. Models that present systemic risks face an additional layer of oversight, including mandatory adversarial testing, red-teaming, model evaluations, cybersecurity protections, and formal incident-reporting mechanisms to the European AI Office.

The AI Office has moved rapidly from policy formulation to active enforcement, establishing its presence in early 2026 by issuing a formal data retention order to X (formerly Twitter) regarding its Grok model, and initiating a market investigation into whether Meta's WhatsApp Business API unfairly restricts rival AI providers.

The MedTech Double Lock: Integrating MDR, IVDR and High-Risk AI Obligations

The regulatory burden is particularly intense for digital health and medical technology startups. In the European clinical context, software with a medical purpose, such as diagnostic imaging software, oncology prediction tools and remote patient monitoring algorithms is already heavily regulated as a medical device. These technologies require comprehensive pre-market assessments to obtain a CE mark under the EU Medical Devices Regulation (MDR) or the In Vitro Diagnostic Regulation (IVDR).

Under the AI Act's horizontal framework, any software that serves as a safety component of a medical device, or is itself a medical device, and must undergo third-party conformity assessment under the MDR or IVDR is automatically classified as a High-Risk AI System (HRAIS). This automatic categorisation subjects medical AI startups to a formidable "double lock".

Compliance with one framework does not substitute for compliance with the other. Instead, developers must run concurrent, integrated compliance programs that address clinical safety under the MDR/IVDR alongside systemic digital risks under the AI Act.

To establish uniform quality standards and address inconsistent practices across the industry, the European Commission adopted Implementing Regulation 2026/977 on May 4th, 2026. This regulation establishes strict, mandatory procedural timelines for Notified Body conformity assessments under the MDR and IVDR:

Application Review: Maximum of 30 days.
Quality Management System (QMS) Audits: Maximum of 120 days.
Product Verification and Auditing: Maximum of 90 days.
Final Certification Issuance: Maximum of 20 days.

The regulation also mandates that Notified Bodies warn manufacturers in advance if projected certification costs are expected to rise by more than 10%, providing detailed justifications for the increases. Despite these efforts to make interactions more predictable, Notified Bodies have raised concerns about severe resource shortages and their physical capacity to meet these aggressive timelines.

Indeed, a perfect storm has formed in 2026 as thousands of legacy medical devices scramble to transition from old directives to the MDR and IVDR ahead of the critical December 31, 2027, and December 31, 2028, deadlines. This massive surge in demand has created a severe bottleneck, with average certification reviews stretching between 13 and 18 months.

For early-stage healthcare startups, these long pre-market delays are a major challenge. The slow certification process drains the limited resources of European medical AI startups, forcing many to turn toward foreign markets. Daniel Kvak, the founder and CEO of Carebot, a Prague-based startup developing AI systems to help surgeons analyse radiological scans, notes that these protracted delays severely impact innovative health tech startups trying to establish themselves quickly in a highly competitive market.

While foreign competitors can launch in lighter regulatory environments to generate early revenue, European founders often find themselves stuck in administrative queues. This structural friction has shifted the venture capital thesis in Europe. Investors are increasingly reluctant to fund the long regulatory timelines of early-stage medical software. Instead, venture capital is flowing toward well-capitalized incumbents who possess the balance sheet depth to navigate the Notified Body bottleneck, transforming regulatory compliance into a powerful defensive moat.

Navigating the Legislative Divide: Digital Omnibus versus DG SANTE Simplification

The structural complexity and high costs of the double lock have triggered a intense policy debate within the European Commission. Regulators are divided over how to resolve the overlap between medical device rules and the AI Act without compromising patient safety or fundamental rights. This debate has yielded two competing legislative proposals that offer contrasting paths to simplification.

The first path, championed by DG CONNECT (Directorate-General for Communications Networks, Content and Technology), is known as the Digital Omnibus. This legislative package aims to streamline compliance while keeping medical AI firmly within the AI Act's high-risk framework. Under this approach, medical devices incorporating AI are kept under the HRAIS classification, but moved to Section B of Annex I of the AI Act.

The Digital Omnibus reduces duplication by allowing designated Notified Bodies to assess AI Act requirements alongside MDR/IVDR requirements in a single, integrated audit process. It also seeks to prevent launch delays by postponing the application of specific AI Act obligations until clear, harmonised technical standards are officially established.

The second, more radical path is the MDR/IVDR Simplification Proposal led by DG SANTE (Directorate-General for Health and Food Safety) under reference COM(2025)1023. This proposal seeks to address the bottleneck by amending the AI Act to change its relationship with medical device rules.

While it also moves the MDR and IVDR to Section B of Annex I, the legal consequence is fundamentally different: medical AI devices are completely exempted from the AI Act’s HRAIS substantive requirements. Under this model, the MDR and IVDR frameworks function as the sole, primary legal frameworks for these technologies.

The European Commission would retain the power to adopt specific delegated or implementing acts in the future to selectively reintroduce certain AI Act requirements, but until those acts are passed, startups would face a single regulatory pathway.

While these proposals are debated, the AI Act Omnibus has provided immediate procedural relief by extending the compliance deadline for high-risk AI medical devices and IVDs to August 2028. This extension gives startups valuable time to update their technical files, align their post-market clinical follow-up processes, and integrate model drift detection systems into their Quality Management Systems. However, this extension does not delay the upcoming August 2026deadlines, which require immediate compliance with transparency rules, synthetic content labeling, and clear disclosures for patient-facing AI chatbots.

The Sovereign Compute Deficit and Existential Geopolitics

Beyond administrative hurdles, Europe's AI ambitions face a physical constraint: a massive, widening gap in data centre capacity and computing power. This infrastructure deficit has structural implications for technological sovereignty, forcing European developers to rely on foreign cloud platforms and hardware.

The geopolitical stakes of this deficit are illustrated in the "Europe 2031" research scenario. This analysis projects a critical scenario where Europe's compute gap with the United States swells from 16 gigawatts to over 200 gigawatts. Under this scenario, Europe's total dependence on foreign hyperscalers leaves it vulnerable to geopolitical pressure. Lacking the physical infrastructure to run critical systems independently, the Union faces a scenarios where access to frontier models could be restricted or conditioned on strategic concessions, such as surrendering control over key technologies like ASML's lithography manufacturing.

This warning has already proved conservative. In mid-June 2026, the United States government instructed Anthropic to block non-US citizens and those based outside the US from accessing its latest "Fable" model—a restriction the authors of the "Europe 2031" scenario had only anticipated occurring in 2029.

This lack of domestic compute capacity is already forcing leading European tech companies to seek partnerships with US tech giants. For years, Germany-based DeepL cornered the global market for high-quality, professional machine translation, processing data exclusively on its own secure, European-based servers.

However, in mid-2026, DeepL announced a partnership with Amazon Web Services (AWS) to access the vital infrastructure and computing capacity needed to train its next-generation models. This move sparked concern among European privacy advocates, illustrating how a lack of domestic computing power can erode technological independence and force compliance-focused firms to rely on foreign providers.

This structural deficit stands in contrast to the potential of the European Health Data Space (EHDS). Designed as a major market maker, the EHDS mandates that clinical data holders (such as public hospitals and clinics) make electronic health data available for research and innovation. This has created a highly valuable asset class: curated, longitudinal clinical data.

Yet, without domestic computing infrastructure to process this data, European startups face a paradox: they have access to clinical datasets, but lack the local hardware capacity to train frontier models at scale, allowing foreign firms with superior computing power to capture much of the value.

The Transatlantic Escape: The US Market and FDA Deregulation

Driven by the high costs of the European "double lock" and limited local infrastructure, a growing number of AI founders are choosing to launch their products in the United States. This trend is accelerated by a major shift in the US regulatory environment. On January 6, 2026, the FDA shifted its stance on enforcement discretion, implementing a coordinated strategy to lower premarket review barriers for digital health and clinical workflow software:

Unlocking Workflow AI: Previously, software was regulated as a medical device requiring a formal 510(k) premarket clearance if it provided "single-output" recommendations, such as flagging a potential diagnosis or suggesting drug dosages. Under the new guidelines, "single-output" clinical decision support tools are exempt from premarket review, provided they are based on established clinical guidelines and allow clinicians to independently review the underlying logic. By acting as a transparent coach rather than a black-box replacement, developers can bypass traditional premarket review entirely.
Broadening General Wellness Boundaries: The FDA has explicitly broadened the general wellness classification to include software that tracks complex biomarkers, such as blood glucose, blood pressure, and Heart Rate Variability (HRV). As long as these applications frame their data around a healthy lifestyle and reducing the risk of chronic conditions—rather than directly diagnosing disease—they can be marketed without requiring 510(k) clearance. This allows consumer wellness platforms like Oura or continuous glucose monitor apps to market their products aggressively for longevity and metabolic health.

While this deregulated lane allows startups to launch quickly and build revenue, it carries a major trade-off. By bypassing formal FDA premarket review, software developers lose their regulatory "shield" in product liability lawsuits. In the US legal system, an FDA clearance serves as a powerful defence against claims of design defects or inadequate testing.

Without this clearance, vendors carry direct product liability. If an exempt AI tool fails or misses a critical diagnosis, the developer faces high litigation risk, creating a "Builder Beware" market where companies must defend their own clinical evidence and carry substantial product liability insurance.

The Sovereign Capital and Decentralised Regulations of the Gulf

The states of the Persian Gulf, particularly the UAE and Saudi Arabia, are pursuing an alternative model of AI development. Rather than relying on a centralised, horizontal law like the EU AI Act, the GCC has built a decentralised regulatory stack that binds companies through practical, commercial channels like public procurement rules, sector licensing, and mandatory free-zone certifications.

The United Arab Emirates

The UAE has established a pro-growth regulatory environment, appointing the world's first Minister of State for AI and deploying substantial infrastructure. In January 2026, the country adopted the UAE National AI System, which acts as an advisory member of the Cabinet, integrating AI policy directly into federal governance.

At the regional layer, the DIFC has implemented Regulation 10, the first horizontal, AI-specific binding instrument in the Middle East. Regulation 10 establishes a clear three-role architecture consisting of the Deployer, Operator, and Provider, and requires companies to obtain independent certifications and appoint a dedicated Autonomous Systems Officer.

This is paired with the DIFC Data Protection Amendment (Law 1 of 2025), which introduces a direct private right of action for data subjects, enabling them to sue for distress damages without needing to prove direct economic loss.

On the infrastructure front, the UAE has secured partnerships with Western technology leaders to build large-scale data centers. Through a US-UAE AI Acceleration Partnership, the UAE has secured access to advanced US semiconductors to support a 5-gigawatt AI campus in Abu Dhabi built by G42, alongside "Stargate UAE"—a 1-gigawatt AI data center supported by OpenAI, NVIDIA, and Oracle.

This massive compute capacity is paired with regulatory flexibility, though US export controls require the UAE to implement strict risk-mitigation measures, including penetration testing, pre-deployment red-teaming of models and rigorous "Know Your Customer" audits.

Saudi Arabia

Saudi Arabia is driving its national AI strategy through the Saudi Data and AI Authority (SDAIA). In March 2026, the Saudi Cabinet designated 2026 as the "Year of AI," reflecting its integration into the Kingdom's economic development plans.

Saudi Arabia’s regulatory framework is driven by practical, procurement-binding mechanisms. In May 2025, SDAIA released seven regulatory instruments, including binding Ethical Principles and an AI Adoption Framework. Crucially, any third-party AI vendor seeking to sell into the Kingdom's public sector or state-backed enterprises is contractually bound to comply with these ethical principles, turning compliance into a direct commercial prerequisite.

To attract global startups, the Ministry of Investment (MISA) offers 0% corporate tax for technology firms and 0% VAT on SaaS exports, drawing over 664 AI companies to establish operations in Riyadh. The Kingdom has backed this ecosystem with $9.1 Billion in AI investments, alongside the construction of the Hexagon Data Center, a 480-megawatt, green-certified facility utilising advanced direct liquid cooling to run large-scale models in extreme desert conditions.

This capital and compute are paired with progressive regulatory reforms, including an open-banking framework that has enabled fintech companies like Tamara to process over $1 Billion annually, and a new copyright law coming into effect on August 1, 2026, which introduces an explicit exception for AI model training data.

European Sandbox Defences and Biotech Policy Reform

Despite regulatory and infrastructure challenges, Europe is taking steps to support its local startup ecosystem. Rather than viewing regulation solely as a constraint, policymakers are designing frameworks to help startups manage compliance and anchor frontier development within the bloc.

A key mechanism for this is the establishment of AI regulatory sandboxes under Articles 57 and 58 of the AI Act. Every Member State must operate at least one national sandbox by August 2026, offering startups a supervised environment to develop, test, and validate innovative AI systems under regulatory oversight before facing full market audits.

Sandboxes are not exemptions from the AI Act; they are supervised pathways to compliance. For early-stage startups, sandbox participation provides direct regulatory guidance, risk-classification reviews, and assistance with conformity assessments free of charge. Under Article 62, startups and SMEs enjoy priority access, while Article 63 simplifies quality-management requirements for micro-enterprises, allowing them to build compliance records that can be reused during formal market launch.

In parallel, the European Commission proposed the EU Biotech Act (Part 1) in December 2025, blending industrial policy with regulatory modernisation. The Biotech Act introduces measures to support clinical development and biotech innovation:

Accelerated Clinical Trials: The Act reforms clinical trial regulations to cut multinational trial approval timelines from 106 to 75 days.
Intellectual Property Incentives: It proposes a 12-month extension to the Supplementary Protection Certificate (SPC) for advanced therapies developed and manufactured within the EU, anchoring clinical development within the Union.
Regulatory Modernisation: It tasks the European Medicines Agency (EMA) with publishing unified guidance on the deployment of AI across the entire life cycle of medicinal products, from pre-clinical research to post-authorisation monitoring.

At the same time, some European startups are choosing to scale within the continent's regulatory framework rather than relocating. In Switzerland, the fintech startup Infinity secured a purely Swiss investor lineup for its autonomous accounting platform, choosing to build within the European regulatory framework to demonstrate that compliant, highly secure systems can scale effectively.

Similarly, Finland's quantum-computing leader IQM bypassed the traditional US relocation route by listing on Nasdaq in New York while executing a simultaneous dual listing on Nasdaq Helsinki, approved by Finland's Financial Supervisory Authority, proving that European deep-tech firms can access global capital while maintaining their domestic footprint.

Furthermore, within the EU-UK Forum, policymakers are exploring a "regulatory learning loop" to systematically exchange insights from their respective reforms, building more flexible, interoperable frameworks across the English Channel.

Comparative Jurisdictional and Economic Analysis

The financial and operational differences across these key jurisdictions highlight the trade-offs founders must navigate.The tables below detail compliance costs, regulatory structures, and the healthcare AI landscape.

High-Risk AI Act Compliance Costs by Firm Size

The financial model below details the estimated setup and annual operational costs for high-risk AI Act compliance, illustrating the high entry barriers for smaller firms.

Employee Count Bracket	Initial QMS Implementation	Conformity Assessment / Audit	Technical File & Documentation	Annual Maintenance & PMS	Primary Compliance Pathway
Micro (<10 Employees)	€80,000 – €150,000	€30,000 – €70,000 (Self-Assessment)	€30,000 – €40,000	€40,000 – €60,000	Simplified QMS & Priority Sandbox.
Mid-Tier (50–100)	€193,000 – €250,000	€50,000 – €80,000 (Third-Party)	€40,000 – €50,000	€80,000 – €100,000	Standard QMS & Notified Body Audit.
SME (100–250)	€250,000 – €330,000	€100,000 – €150,000 (Third-Party)	€50,000 – €60,000	€100,000 – €125,000	Full ISO 13485 & Dedicated Counsel.
Large (250–500)	€330,000 – €500,000	€100,000 – €150,000 (Third-Party)	€50,000 – €60,000	€125,000 – €150,000	Integrated Corporate PMS Systems.

Jurisdictional Framework Comparison

The structural approaches of the major AI markets show a clear divergence between ex-ante risk mitigation and infrastructure-led development.

Comparative Dimension	European Union	United States	United Arab Emirates	Saudi Arabia
Primary Philosophy	Rights-Based & Precautionary.	Market-Led & Innovation-First.	Infrastructure-First & Agile.	State-Led Transformation.
Enforcement Mechanism	Centralised horizontal AI Act.	State-level bills & FTC guidelines.	Four-layer stack (DIFC, PDPL).	SDAIA binding ethics & PDPL rules.
Ex-Ante Launch Barriers	High (MDR/IVDR + HRAIS reviews).	Low (Exemptions for CDS/Wellness).	Medium (DIFC Sandboxes & Certs).	Low (Procurement contract audits).
Sovereign Infrastructure	Large 16GW+ compute deficit.	Leading (Vast private hyperscalers).	Stargate UAE (1GW), G42 Campus.	Hexagon DC (480MW), Shaheen III.
Maximum Penalties	€35M or 7% of global turnover.	Post-hoc product liability damages.	DIFC private distress damages.	PDPL criminal and corporate fines.

Healthcare & Infrastructure AI Startup Strategy

The landscape of healthcare AI platforms illustrates how successful players structure their technology and data pipelines to align with local regulatory demands.

Platform / Startup	Core Clinical Sector	Primary Jurisdiction	Notable Achievement	Regulatory & Technical Strategy
Tempus AI	Precision Oncology.	United States.	Large clinical genomic dataset.	Built a proprietary genomic data moat wrapped in SaMD clearances.
DeepL	Machine Translation.	Germany.	Professional translation scale.	Transitioned to AWS servers due to European compute constraints.
Hathr.AI	Medical Coding.	Europe / Global.	Automated CPT/ICD-10 clinical coding.	Operates as a low-risk workflow tool with near-100% accuracy.
Owkin	Federated TechBio.	France.	GDPR-compliant pharma pipeline.	Leverages EHDS and privacy-by-design for clinical modeling.
Carebot	Clinical Diagnostics.	Czech Republic.	AI-enabled radiological scans.	Faced major resource drain waiting for Notified Body reviews.
Infinity	SME Accounting.	Switzerland.	Autonomous accounting without manual entry.	Scaled within Europe using a purely local investor lineup.
Riyadh Air	Corporate HR.	Saudi Arabia.	Agentic HR operations from day one.	Utilises IBM watsonx Orchestrate to manage automated operations.

Conclusion: The Asymmetric Moat and Strategic Workarounds

The question of whether the EU AI Act represents a protective moat or a compliance millstone is resolved by the size and capitalisation of the organisation in question. For well-capitalised incumbents, the layered regulatory stack of the MDR, IVDR, and AI Act functions as a powerful, defensible moat. By compounding existing certifications, clinical trial registries, and exclusive partnerships with clinical data networks under the EHDS, large players can establish first-mover advantages that are difficult for new entrants to challenge.

For early-stage, AI-native startups, however, this regulatory environment is an administrative and financial millstone. The high upfront costs of QMS integration, long delays in Notified Body audits, and a lack of local computing power create barriers that can drain startup resources.

Consequently, a clear strategic divergence has emerged:

By sequencing their development across multiple markets, next-generation founders do not have to abandon the European market. Instead, they can treat the US and the Gulf as engines for rapid product scaling and cash-flow generation, returning to Europe only when they possess the financial runway and institutional backing to transform its complex regulations into their own defensive moat.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech